CYC-116

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NameCYC-116

Drug Alias NameCYC-116

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitorsVascular endothelial growth factor receptor 2 antagonistsSerine/threonine-protein kinase Aurora-C inhibitors +[4]

TargetsSerine/threonine-protein kinase Aurora-AVascular endothelial growth factor receptor 2Serine/threonine-protein kinase Aurora-C +[4]

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCyclacel Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCyclacel Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A